Mphasis DSO reversal and platform flip-flop cloud Tria launch momentum

What's new

• Q1 FY27 revenue $471M, up 2.1% sequential CC growth.
• DSO deteriorated to 95 days from an adjusted 86 days in prior quarter.
• Pipeline reached all-time high at 2.8x original size; AI-led opportunities at 70%.
• Tria platform launched 7 weeks before call, with early demand compression.

Themes from the call

Key quotes

• "FY27 is the year where the platform-first thesis begins to show up in the growth trajectory, not just in pipeline metrics."

  — Nitin Rakesh, CEO

• "That is why Mphasis Modernize and Mphasis Optimize are not separate offerings. They are connected product motions on the same Tria platform."

  — Management, Jul 2026 call

The brief

Mphasis entered FY27 with a strong bookings quarter and early signs that its new Tria platform is gaining traction. Revenue rose 2.1% sequentially to $471 million, the pipeline hit a record 2.8 times its original size, and 70% of wins were AI-led. The Tria platform, launched just seven weeks before the call, is already compressing demand: multiple opportunities moved from discussion to close to execution within weeks. CEO Nitin Rakesh positioned FY27 as the year the platform-first thesis converts into revenue acceleration.

But two contradictions undercut the narrative. DSO deteriorated to 95 days from an adjusted 86 days last quarter — a seven-year high and a sharp reversal from the improving trend management noted in April. The explanation was a single sentence: expect progressive improvement through the year. No reason was given for the jump. Separately, NeoIP — the flagship AI platform in January and April — vanished from the call. It was replaced by Tria, presented as the platform connecting Modernize and Optimize. Management did not explain whether Tria rebrands, replaces, or subsumes NeoIP. For a company whose AI strategy is central to its valuation, that silence is a credibility gap.

Margins also took a hit: EBITDA was down 60 basis points, partly from acquisition costs and deliberate utilization investment ahead of growth. Insurance revenue paused sequentially after four strong quarters, and transformation staffing is temporarily weighing on profitability. Management expects insurance margins to normalize in two quarters and Tria attach rates to expand gross margins in two to three quarters.

The guidance is wide. Q2 growth will be the best sequential in three years — but management refused to name a number. FY27 growth is high single-digit to low double-digit, EBIT margin within 14.8-15.8%, and operating cash flow conversion above 80%. The Redux customer-contract consolidation will contribute only a partial quarter in Q2, with work starting near August end. Exact revenue from that deal is undisclosed.

Mphasis has strong bookings and a plausible platform bet. But the DSO reversal and the unexplained NeoIP-Tria transition raise questions about execution and communication that need answers before the FY27 growth story can be underwritten.